Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 20/20 | 0.59 |
| ▸ | DRD2 | P14416 | 15/20 | 0.59 |
| ▸ | HTR1A | P08908 | 3/20 | 0.59 |
| ▸ | DRD4 | P21917 | 3/20 | 0.59 |
| ▸ | HTR2B | P41595 | 3/20 | 0.59 |
| ▸ | HTR2A | P28223 | 17/20 | 0.56 |
| ▸ | HTR2C | P28335 | 2/20 | 0.54 |
| ▸ | DRD1 | P21728 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL230790 | 1.00 | DRD3 (0.59) | DRD3DRD2HTR1ADRD4HTR2B | |
| SCHEMBL227310 | 0.84 | DRD3 (0.61) | DRD3DRD2HTR1ADRD4HTR2B | |
| SCHEMBL27737767 | 0.84 | DRD3 (0.48) | DRD3DRD2HTR2A | |
| SCHEMBL229129 | 0.83 | DRD2 (0.57) | DRD3DRD2HTR1AHTR2A | |
| SCHEMBL3080642 | 0.80 | DRD3 (0.61) | DRD3DRD2HTR1ADRD4HTR2B | |
| SCHEMBL14715626 | 0.80 | DRD3 (0.61) | DRD3DRD2HTR1ADRD4HTR2B | |
| SCHEMBL228979 | 0.78 | NPC1 (0.50) | HTR1A | |
| SCHEMBL227460 | 0.78 | DRD2 (0.38) | DRD3DRD2HTR1ADRD4HTR2B | |
| SCHEMBL228215 | 0.78 | DRD3 (0.51) | DRD3DRD2HTR1AHTR2A | |
| SCHEMBL228419 | 0.78 | DRD2 (0.42) | DRD3DRD2HTR2BHTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8039490-B2 | Benzoyl-piperidine derivatives as dual modulators of the 5-HT2A and D3 receptors | HOFFMANN-LA ROCHE INC. (US) | 2011-10-18 | — | — | US | claimed |
| US-20070197531-A1 | Benzoyl-piperidine derivatives as dual modulators of the 5-HT2A and D3 receptors | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-08-23 | — | — | US | claimed |
| US-8415350-B2 | Benzoyl-piperidine derivatives as dual modulators of the 5-HT2A and D3 receptors | HOFFMANN-LA ROCHE INC. (US) | 2013-04-09 | — | — | US | disclosed |
| US-20120004208-A1 | BENZOYL-PIPERIDINE DERIVATIVES AS DUAL MODULATORS OF THE 5-HT2A AND D3 RECEPTORS | GOBBI LUCA (CH) | 2012-01-05 | — | — | US | disclosed |
| US-8039490-B2 | Benzoyl-piperidine derivatives as dual modulators of the 5-HT2A and D3 receptors | HOFFMANN-LA ROCHE INC. (US) | 2011-10-18 | — | — | US | disclosed |
| US-20070197531-A1 | Benzoyl-piperidine derivatives as dual modulators of the 5-HT2A and D3 receptors | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004208-A1 | BENZOYL-PIPERIDINE DERIVATIVES AS DUAL MODULATORS OF THE 5-HT2A AND D3 RECEPTORS | HTR2A, HTR3A, HTR2C | DRD3 18/4885DRD2 16/4885HTR1A 6/4885 |
| US-20070197531-A1 | Benzoyl-piperidine derivatives as dual modulators of the 5-HT2A and D3 receptors | HTR2A, HTR3A, HTR2C | DRD3 18/4885DRD2 16/4885HTR1A 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.